First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
Submitted by karen.duncan on Mon, 07/10/2023 - 15:25- Precision-designed potent and selective CDK7 inhibitor with potential for improved therapeutic index -